Generic Name: idelalisib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Gilead Sciences

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.

General Info

Zydelig inhibits phosphatidylinositol-3-kinase (PI3K), an enzyme that is part of signaling pathways that play a role in cell growth and metabolism. It is active against PI3K on cancerous B cells, which grow out of control in people with leukemia and lymphoma.

A study of people with chronic lymphocytic leukemia showed that Zydelig slows disease progression. It received accelerated approval for follicular lymphoma and small lymphocytic lymphoma based on promising response rates in clinical trials.


Dosing Info:

Zydelig is taken as a twice-daily pill.

Side Effects

Common side effects include fatigue, diarrhea, nausea, fever, cough and pneumonia. Zydelig can cause depletion of white blood cells (neutropenia), which can lead to infections. Potentially serious side effects include liver toxicity, colon inflammation (colitis), intestinal damage, lung inflammation (pneumonitis) and severe skin reactions.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 21, 2018